REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Javier Martín‐Broto; Claudia Valverde; Nadia Hindi; Bruno Vincenzi; Javier Martínez‐Trufero; Giovanni Grignani; Antoîne Italiano; Javier Lavernia; Ana Vallejo‐Benítez; Angelo Paolo Dei Tos; François Le Loarer; Ricardo González‐Cámpora; Rafael Ramos; Diana Hernández-Jover; Antonio Gutiérrez; César Serrano; María Monteagudo; Rocío Letón; Mercedes Robledo; David S. Moura; Marta Martín‐Ruíz; José Antonio López‐Guerrero; Julia Cruz; Antonio Fernández‐Serra; Jean Yves Blay; Elena Fumagalli; Virginia Martínez-Marín

doi:10.1186/s12943-023-01832-9

Article2021

1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Javier Martín‐Broto, Claudia Valverde, Nadia Hindi, Bruno Vincenzi, Javier Martínez‐Trufero, Giovanni Grignani, Antoîne Italiano, Javier Lavernia, Ricardo González‐Cámpora, Diana Hernández-Jover, Antonio Gutiérrez, César Serrano, David S. Moura, José Antonio López‐Guerrero, Julia Cruz, Antonio Fernández‐Serra, Jean Yves Blay, Elena Fumagalli, Virginia Martínez Marín

Article2020

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martín‐Broto, Antonio López–Pousa, Giovanni Grignani, Antonella Brunello, Jean Yves Blay, Oscar Tendero, Robert Díaz Beveridge, Virginia Ferraresi, Iwona Ługowska, Domenico Franco Merlo, Valeria Fontana, Emanuela Marchesi, Luca Braglia, Davide María Donati, Elena Palassini, Giuseppe Bianchi, Andrea Marrari, Carlo Morosi,

Article2024

Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martín‐Broto, Antonio López–Pousa, Giovanni Grignani, Antonella Brunello, Jean Yves Blay, Oscar Tendero, Robert Díaz Beveridge, Virginia Ferraresi, Iwona Ługowska, Sara Pizzamiglio, Paolo Verderio, Valeria Fontana, Davide María Donati, Elena Palassini, Roberta Sanfilippo, Giuseppe Bianchi, Alexia Bertuzzi,

Corrigendum2025

Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”

Emmanuelle Bompas, A. Le Cesne, Emmanuelle Tresch‐Bruneel, Loïc Lebellec, Valérie Laurence, Olivier Collard, Esma Saâda-Bouzid, Nicolás Isambert, Jean Yves Blay, Éric Amela, Sébastien Salas, Christine Chevreau, François Bertucci, Antoine Italiano, Stéphanie Clisant, Nicolas Penel

Article2001

Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group

D. Pectasides, Gerasimos Aravantinos, Haralabos P. Kalofonos, Christos Kiamouris, D. Bafaloukos, Nikolaos I. Xiros, C. Nicolaides, A. Visvikis, Meletios A Dimopoulos

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Abstract

Discussion(0)

Related publications

1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)

Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”

Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group